

WHAT IS CLAIMED IS:

1. A carrier:nucleic acid complex comprising nucleic acid encoding at least one anti-angiogenic protein or peptide, the complex being delivered by injection whereby the anti-angiogenic nucleic acid is expressed to inhibit tumor growth.
2. The complex of claim 1, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles, microspheres, viruses, viral components, or combinations of such carriers.
3. The complex of claim 1, wherein the nucleic acid within the complex is comprised of DNA or RNA.
4. The complex of claim 1, wherein the complex additionally contains nucleic acid encoding a tumor suppressor protein.
5. The complex of Claim 2, wherein the complex additionally contains nucleic acid encoding a tumor suppressor protein.
6. The complex of claim 3, wherein the tumor suppressor protein is p53.
7. The complex of claim 4, wherein the tumor suppressor protein is p53.
8. The complex of claim 1, additionally comprising a marker directing the complexes in vivo to a tumor or to tumor or peritumoral area.
9. The complex of claim 1, wherein the nucleic acid is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25; SEQ ID NO:27, SEQ ID NO:31; SEQ ID NO:35; and SEQ ID NO: 37.
10. The complex of claim 1, wherein the anti-angiogenic DNA is

provided in a vector containing at least one promotor.

- 5
11. A method for inhibiting tumor growth in a subject bearing a tumor, which comprises administering to the subject nucleic acid encoding at least one anti-angiogenic protein or peptide in a carrier whereby nucleic acid is expressed and tumor growth is inhibited.
12. The method of claim 11, wherein the carrier is selected from the group consisting of liposomes, cationic polymers, micelles, microspheres, viruses, viral components, or combinations of such carriers.
- 10
13. The method of claim 11, which further comprises providing a DNA encoding a tumor suppressor protein on the carrier.
14. The method of claim 11, wherein the administration is by injection.
- 15
15. The method of claim 13, wherein the administration is by injection.
16. The method of claim 14, wherein the injection is intravenous injection.
17. The method of claim 15, wherein the injection is intravenous injection.
- 20
18. A method of inhibiting tumor growth in a subject bearing a tumor, which comprises injecting the subject with anti-angiogenic nucleic acid in a form in which the DNA is expressed in the tumor or a peritumoral area.
- 25
19. The method of claim 18, wherein nucleic acid encoding a tumor suppressor protein is additionally injected in a form which is expressed in the tumor or associated tumor vasculature.
20. The method of claim 18, wherein the injection is intravenous.